Prof. Weijian Guo 郭伟剑
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy for malignant tumors and comprehensive treatment of digestive tract cancers.
Dr. Guo is a Chief Physician, Professor, and Director of the Digestive Tumor Subspecialty at Fudan University Shanghai Cancer Center. Dr. Guo earned a clinical medicine doctorate from Shanghai Medical University (1994–1999) and completed postdoctoral research at Northwestern University, USA (2005–2007). Dr. Guo has led projects funded by the National Natural Science Foundation and published over 30 papers.
Professional roles
- Standing Committee Member, Precision Medicine Committee, China Anti-Cancer Association
- Standing Committee Member, Pancreatic Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
- Former Chair, Cancer Rehabilitation and Palliative Care Committee, Shanghai Anti-Cancer Association
- Vice Chair, Gastric Cancer Molecular Targeted and Immunotherapy Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Guo Weijian). Papers usually list the name as Weijian Guo or Guo W.
Selected publications
105 papers on PubMed matched by name and affiliation; 49 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Res, 2026 (senior author): A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer. PubMed 42630712
- Transl Oncol, 2026 (senior author): Circular RNA circSCMH1 regulates glycolysis to inhibit gastric cancer metastasis via miR-296-3p/HSPB7-GLUT3 axis. PubMed 41401631
- Diagn Pathol, 2025 (senior author): Development and validation of a gastric cancer prognostic model utilizing lymphatic endothelial cell-related genes. PubMed 40926266
- Cancer Biol Med, 2025 (senior author): Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling. PubMed 39985133
- MedComm (2020), 2024 (senior author): LINC01764 promotes colorectal cancer cells proliferation, metastasis, and 5-fluorouracil resistance by regulating glucose and glutamine metabolism via promoting c-MYC translation. PubMed 39534558
- J Hematol Oncol, 2024 (senior author): Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial. PubMed 39529169
- Adv Ther, 2024 (senior author): Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study. PubMed 39276185
- Cell Death Dis, 2024 (senior author): The ubiquitin-like protein UBTD1 promotes colorectal cancer progression by stabilizing c-Myc to upregulate glycolysis. PubMed 39003255
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion